273 related articles for article (PubMed ID: 35073677)
1. [Immunogenicity and safety of a booster vaccination with an inactivated severe acute respiratory syndrome coronavirus 2 vaccine in adults aged 18 to 59 years].
Pan HX; Huang BY; Deng Y; Chu K; Hu JL; Zhu DD; Wu JL; Zhang L; Wang M; Huang WJ; Tan WJ
Zhonghua Yi Xue Za Zhi; 2022 Jan; 102(4):279-285. PubMed ID: 35073677
[No Abstract] [Full Text] [Related]
2. Safety and immunogenicity against ancestral, Delta and Omicron virus variants following a booster dose of an inactivated whole-virus COVID-19 vaccine (VLA2001): Interim analysis of an open-label extension of the randomized, controlled, phase 3 COV-COMPARE trial.
Taucher C; Lazarus R; Dellago H; Maurer G; Weisova P; Corbic-Ramljak I; Dubischar K; Lilja A; Eder-Lingelbach S; Hochreiter R; Jaramillo JC; Junker H; Krammer M; Pusic P; Querton B; Larcher-Senn J; Hoffmann M; Pöhlmann S; Finn A;
J Infect; 2023 Sep; 87(3):242-254. PubMed ID: 37406777
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials.
Zeng G; Wu Q; Pan H; Li M; Yang J; Wang L; Wu Z; Jiang D; Deng X; Chu K; Zheng W; Wang L; Lu W; Han B; Zhao Y; Zhu F; Yu H; Yin W
Lancet Infect Dis; 2022 Apr; 22(4):483-495. PubMed ID: 34890537
[TBL] [Abstract][Full Text] [Related]
4. Safety, immunogenicity, and efficacy of the mRNA vaccine CS-2034 as a heterologous booster versus homologous booster with BBIBP-CorV in adults aged ≥18 years: a randomised, double-blind, phase 2b trial.
Wu JD; Li JX; Liu J; Wang HM; Zhou GH; Li J; Wu D; Chen X; Feng Y; Qi XY; Wang X; Gou JB; Ma TL; Yang XY; Xu LF; Wan P; Zhu T; Wang ZF; Zhu FC;
Lancet Infect Dis; 2023 Sep; 23(9):1020-1030. PubMed ID: 37216958
[TBL] [Abstract][Full Text] [Related]
5. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity and Safety of a 3-Dose Regimen of a SARS-CoV-2 Inactivated Vaccine in Adults: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial.
Liu J; Huang B; Li G; Chang X; Liu Y; Chu K; Hu J; Deng Y; Zhu D; Wu J; Zhang L; Wang M; Huang W; Pan H; Tan W
J Infect Dis; 2022 May; 225(10):1701-1709. PubMed ID: 34958382
[TBL] [Abstract][Full Text] [Related]
7. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial.
Xia S; Zhang Y; Wang Y; Wang H; Yang Y; Gao GF; Tan W; Wu G; Xu M; Lou Z; Huang W; Xu W; Huang B; Wang H; Wang W; Zhang W; Li N; Xie Z; Ding L; You W; Zhao Y; Yang X; Liu Y; Wang Q; Huang L; Yang Y; Xu G; Luo B; Wang W; Liu P; Guo W; Yang X
Lancet Infect Dis; 2021 Jan; 21(1):39-51. PubMed ID: 33069281
[TBL] [Abstract][Full Text] [Related]
8. Safety, immunogenicity and protection of heterologous boost with an aerosolised Ad5-nCoV after two-dose inactivated COVID-19 vaccines in adults: a multicentre, open-label phase 3 trial.
Li JX; Hou LH; Gou JB; Yin ZD; Wu SP; Wang FZ; Zhang Z; Peng ZH; Zhu T; Shen HB; Chen W; Zhu FC;
Lancet Infect Dis; 2023 Oct; 23(10):1143-1152. PubMed ID: 37352880
[TBL] [Abstract][Full Text] [Related]
9. Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials.
Xia S; Duan K; Zhang Y; Zhao D; Zhang H; Xie Z; Li X; Peng C; Zhang Y; Zhang W; Yang Y; Chen W; Gao X; You W; Wang X; Wang Z; Shi Z; Wang Y; Yang X; Zhang L; Huang L; Wang Q; Lu J; Yang Y; Guo J; Zhou W; Wan X; Wu C; Wang W; Huang S; Du J; Meng Z; Pan A; Yuan Z; Shen S; Guo W; Yang X
JAMA; 2020 Sep; 324(10):951-960. PubMed ID: 32789505
[TBL] [Abstract][Full Text] [Related]
10. Safety and immunogenicity of the inactivated whole-virus adjuvanted COVID-19 vaccine VLA2001: A randomized, dose escalation, double-blind phase 1/2 clinical trial in healthy adults.
Lazarus R; Taucher C; Brown C; Čorbic Ramljak I; Danon L; Dubischar K; Duncan CJA; Eder-Lingelbach S; Faust SN; Green C; Gokani K; Hochreiter R; Wright JK; Kwon D; Middleditch A; Munro APS; Naker K; Penciu F; Price D; Querton B; Riaz T; Ross-Russell A; Sanchez-Gonzalez A; Wardle H; Warren S; Finn A;
J Infect; 2022 Sep; 85(3):306-317. PubMed ID: 35718205
[TBL] [Abstract][Full Text] [Related]
11. Safety and immunogenicity of an inactivated whole virion SARS-CoV-2 vaccine, TURKOVAC, in healthy adults: Interim results from randomised, double-blind, placebo-controlled phase 1 and 2 trials.
Ozdarendeli A; Sezer Z; Pavel STI; Inal A; Yetiskin H; Kaplan B; Uygut MA; Bayram A; Mazicioglu M; Unuvar GK; Yuce ZT; Aydin G; Aslan AF; Kaya RK; Koc RC; Ates I; Kara A
Vaccine; 2023 Jan; 41(2):380-390. PubMed ID: 36460536
[TBL] [Abstract][Full Text] [Related]
12. Safety and immunogenicity of a live-attenuated influenza virus vector-based intranasal SARS-CoV-2 vaccine in adults: randomised, double-blind, placebo-controlled, phase 1 and 2 trials.
Zhu F; Zhuang C; Chu K; Zhang L; Zhao H; Huang S; Su Y; Lin H; Yang C; Jiang H; Zang X; Liu D; Pan H; Hu Y; Liu X; Chen Q; Song Q; Quan J; Huang Z; Zhong G; Chen J; Han J; Sun H; Cui L; Li J; Chen Y; Zhang T; Ye X; Li C; Wu T; Zhang J; Xia NS
Lancet Respir Med; 2022 Aug; 10(8):749-760. PubMed ID: 35644168
[TBL] [Abstract][Full Text] [Related]
13. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study.
Costa Clemens SA; Weckx L; Clemens R; Almeida Mendes AV; Ramos Souza A; Silveira MBV; da Guarda SNF; de Nobrega MM; de Moraes Pinto MI; Gonzalez IGS; Salvador N; Franco MM; de Avila Mendonça RN; Queiroz Oliveira IS; de Freitas Souza BS; Fraga M; Aley P; Bibi S; Cantrell L; Dejnirattisai W; Liu X; Mongkolsapaya J; Supasa P; Screaton GR; Lambe T; Voysey M; Pollard AJ;
Lancet; 2022 Feb; 399(10324):521-529. PubMed ID: 35074136
[TBL] [Abstract][Full Text] [Related]
14. Long-term immunogenicity and safety of heterologous boosting with a SARS-CoV-2 mRNA vaccine (SYS6006) in Chinese participants who had received two or three doses of inactivated vaccine.
Huang J; Qiu Y; Luo L; Wu J; Hu D; Zhong X; Lin J; Guo L; Yang H; Li C; Wang X
J Med Virol; 2024 Mar; 96(3):e29542. PubMed ID: 38506170
[TBL] [Abstract][Full Text] [Related]
15. Safety and immunogenicity of Ad5-nCoV immunization after three-dose priming with inactivated SARS-CoV-2 vaccine in Chinese adults.
Zhang H; Xu N; Xu Y; Qin P; Dai R; Xu B; Wang S; Ding L; Fu J; Zhang S; Hua Q; Liao Y; Yang J; Hu X; Jiang J; Lv H
Nat Commun; 2023 Aug; 14(1):4757. PubMed ID: 37553338
[TBL] [Abstract][Full Text] [Related]
16. Safety and immunogenicity of heterologous boost immunization with an adenovirus type-5-vectored and protein-subunit-based COVID-19 vaccine (Convidecia/ZF2001): A randomized, observer-blinded, placebo-controlled trial.
Jin P; Guo X; Chen W; Ma S; Pan H; Dai L; Du P; Wang L; Jin L; Chen Y; Shi F; Liu J; Xu X; Zhang Y; Gao GF; Chen C; Feng J; Li J; Zhu F
PLoS Med; 2022 May; 19(5):e1003953. PubMed ID: 35617368
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity and safety of single booster dose of KD-414 inactivated COVID-19 vaccine in adults: An open-label, single-center, non-randomized, controlled study in Japan.
Terada-Hirashima J; Takamatsu Y; Shimizu Y; Uemura Y; Takeuchi JS; Tomita N; Matsuda K; Maeda K; Yamamoto S; Fukunaga A; Ohmagari N; Mikami A; Sonoda K; Ujiie M; Mitsuya H; Sugiura W
Hum Vaccin Immunother; 2023 Dec; 19(1):2193074. PubMed ID: 37052247
[TBL] [Abstract][Full Text] [Related]
18. Safety and immunogenicity of a bivalent SARS-CoV-2 protein booster vaccine, SCTV01C, in adults previously vaccinated with mRNA vaccine: a randomized, double-blind, placebo-controlled phase 1/2 clinical trial.
Hannawi S; Saifeldin L; Abuquta A; Alamadi A; Mahmoud SA; Hassan A; Liu D; Yan L; Xie L
EBioMedicine; 2023 Jan; 87():104386. PubMed ID: 36470077
[TBL] [Abstract][Full Text] [Related]
19. Safety and immunogenicity of inactivated COVID-19 vaccine in patients with metabolic syndrome: A cross-sectional observational study.
Guo Q; Yang L; Peng R; Gao T; Chu X; Jiang D; Ke D; Ren H
Front Public Health; 2022; 10():1067342. PubMed ID: 36620297
[TBL] [Abstract][Full Text] [Related]
20. Safety and immunogenicity of inactive vaccines as booster doses for COVID-19 in Türkiye: A randomized trial.
Omma A; Batirel A; Aydin M; Yilmaz Karadag F; Erden A; Kucuksahin O; Armagan B; Güven SC; Karakas O; Gokdemir S; Altunal LN; Buber AA; Gemcioglu E; Zengin O; Inan O; Sahiner ES; Korukluoglu G; Sezer Z; Ozdarendeli A; Kara A; Ates I
Hum Vaccin Immunother; 2022 Nov; 18(6):2122503. PubMed ID: 36315843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
